Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved: Figure 1

Prostate cancer is a major and increasing public health burden. Androgen suppression therapy (AST) for prostate cancer provides well-established benefits in advanced stages of the disease. Unfortunately, mounting evidence suggests an association between AST and increased risk of cardiovascular disease (CVD). In this viewpoint, the authors seek to raise awareness of an underappreciated problem, summarise the evidence linking AST and CVD risk, and highlight important research questions that need to be addressed. Given the lack of a clear evidence base with which to dictate, the authors discuss possible management options and how these might be integrated into existing care pathways.